Asia Pacific Medical Foods Market (2026 - 2033)

Asia Pacific Medical Foods Market Summary

The Asia Pacific medical foods market size was valued at USD 7.3 billion in 2025 and is projected to grow from USD 7.8 billion in 2026 to USD 11.9 billion by 2033, at a CAGR of 6.2% from 2026 to 2033. China dominated the market, accounting for the largest revenue share of 33.0% in 2025. The region has a large patient pool and geriatric population, and lifestyle changes are leading to an increase in the prevalence of various diseases, such as cancer, diabetes, gastrointestinal disorders, & autoimmune diseases.

According to data published by the WHO in February 2023, Thailand had 12 million elderly people out of a population of 67 million, with the elderly population expected to reach 28% within the next decade, increasing the demand for medical foods to address age-related nutritional needs.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Market Dynamics

The industry is witnessing significant growth, driven by the rising prevalence of chronic diseases, increasing nutritional deficiencies, and growing demand for specialized nutrition among preterm infants and aging populations. Expanding healthcare infrastructure, greater awareness of disease-specific nutrition, and increasing adoption of specialized dietary products are supporting market expansion. In addition, rising healthcare expenditure and advancements in medical nutrition formulations are expected to sustain market growth over the forecast period.

Market Concentration & Characteristics

The degree of innovation in the industry is high. Leading manufacturers are focusing on increasing partnerships with hospitals and are targeting different population cohorts to gain large market shares. For instance, in August 2024, Danone India (NIPL) and Apollo 24|7 partnered to launch the Super 6 Diabetes Program, targeting India’s growing diabetes epidemic. As the exclusive nutrition partner, Danone would provide Protinex Diabetes Care (PDC), formulated as a Food for Special Dietary Use (FSDU) to support diabetes management. PDC features high dietary fiber for gradual sugar absorption, reduced carbohydrates, and a low Glycemic Index (GI) to help regulate blood sugar levels.

Mergers, acquisitions, and strategic partnerships enable companies to expand their geographic presence, strengthen manufacturing and supply chain capabilities, and enhance their specialized nutrition portfolios. For instance, in August 2025, The a2 Milk Company acquired Yashili New Zealand Dairy Co. Limited from China Mengniu Group for approximately NZD 282 million. The acquisition strengthened the company's manufacturing and supply chain capabilities and supported its expansion in China's infant nutrition market, thereby contributing to the growth of the regional medical foods market.

To learn more about this report, Download Free Sample Report

The industry is subject to moderate regulatory impact, as regulatory requirements govern product composition, labeling, safety, and market authorization. For instance, in Australia and New Zealand, Standard 2.9.5 of the Food Standards Code regulates the composition, labeling, and sale of foods for special medical purposes (FSMPs), with requirements broadly aligned with international regulatory frameworks. These regulations ensure product safety and quality while influencing market entry and product commercialization.

Geographic expansion drives the industry by enabling access to diverse resources, increasing market penetration and revenue, and fostering regulatory compliance and standardization. For instance, in November 2023, Danone launched its first medical nutrition product, Fortimel, for adults in China, categorized under foods for special medical purposes. This launch is a crucial component of Danone’s strategy in China, aimed at utilizing its scientific expertise across all life stages and promoting the growth of the adult medical nutrition segment.

“The launch of Fortimel Balanced is another milestone on Danone’s ‘Innovated in China, Made in China’ journey. The product leverages Danone’s cutting-edge science and research capability to cater to the nutritional needs of Chinese patients. It marks a solid step into the aFSMP market in China, and helps Danone to further grow its portfolio covering the full life spectrum.”

- Bruno Chevot, Danone’s President China, North Asia and Oceania

Analyst Perspective

The industry is driven by the rising prevalence of chronic and metabolic disorders, the increasing geriatric population, and growing awareness of specialized nutritional products. Expanding healthcare expenditure, improving access to clinical nutrition, and rising demand for disease-specific dietary solutions are supporting market development. In addition, increasing investments by manufacturers in product innovation and distribution expansion are expected to create new growth opportunities, while growing adoption of medical foods in hospitals and home-care settings is likely to sustain long-term market expansion.

Route of Administration Insights

The oral segment led the market and accounted for 73.4% of the total revenue in 2025. Increased preference for orally administered products, commercial viability, and supportive initiatives drive the demand for medical foods. Generally, most people requiring Oral Nutritional Supplements (ONS) are treated using standard ONS products with a calorific value of 1.5 to 2.4 Kcal/ml. These products are available in different flavors to suit patient requirements. Moreover, increased preference for orally administered products, commercial viability, and supportive initiatives are key factors driving the demand for orally administered medical foods.

The enteral segment is expected to witness the fastest growth over the forecast period. The demand for enteral feeding formulas is increasing due to the rising prevalence of chronic diseases, such as cancer and cardiovascular diseases, which may lead to metabolic complications and difficulty in consuming food during treatment. In critically ill patients, enteral nutrition plays an important role in preventing undernutrition and loss of lean body mass, particularly during catabolic states associated with systemic inflammation. The growing adoption of enteral nutrition in critical care settings and increasing awareness of its clinical benefits are expected to support segment growth in the market.

Product Insights

The powder segment accounted for the largest revenue share of 36.0% in 2025. Medical foods are mostly available in powder form, which can be administered through the oral route or enteral route by mixing with milk or water, as advised by the physician. Medical foods in the powdered formula are suitable for patients of all age groups, especially in the oral route. Owing to a high preference for powdered formulations due to ease of consumption, manufacturers are developing product categories in line with consumer preferences.

The liquid segment is anticipated to grow at the fastest CAGR during the forecast period, owing to the rising adoption of liquid formulations in the pediatric and geriatric population, where the intake of solid formulations is limited or impossible, and in cases of clinically diagnosed dysphagia or when oral physiology is limited. Moreover, liquid-formulated food helps to maintain the sufficient hydration and electrolyte balance, thereby supporting segment growth.

Application Insights

The cancer segment dominated the market with the largest revenue share of 12.3% in 2025. The segment is driven by the rising prevalence of cancer and the growing incidence of malnutrition among patients undergoing cancer treatment. Increasing adoption of specialized medical foods to support nutritional requirements, maintain body weight, and manage treatment-related nutritional deficiencies is expected to further drive segment growth. For instance, in August 2024, the release of the Clinical Oncology Society of Australia (COSA) Cancer-related Malnutrition and Sarcopenia Implementation Toolkit provided multidisciplinary healthcare professionals in Australia with a practical resource to improve the management of malnutrition and sarcopenia in cancer patients. This toolkit follows COSA's national Position Statement on Cancer-Related Sarcopenia and Malnutrition, emphasizing the need for standardized practices to address these conditions. Cancer-related malnutrition and sarcopenia, affecting one in three cancer patients, are expected to contribute to market growth.

The Parkinson's Disease (PD) segment is expected to grow at the fastest CAGR during the forecast period, driven by the rising prevalence of neurodegenerative disorders and increasing demand for specialized nutritional support. Medical foods containing omega-3 fatty acids, coenzyme Q, and vitamins D and B, along with ketogenic diets and probiotics, are increasingly being explored to support nutritional management and complement pharmacological treatment, thereby driving segment growth.

Modules Insights

The protein module segment dominated the market with the largest revenue share of 12.9% in 2025. Protein modules are used in severe infections, trauma, burns, malnutrition, post-surgery recovery, and critically ill patients. The increasing prevalence of chronic diseases, such as cancer, chronic kidney disease, and malnutrition, which require specialized nutritional interventions likely drive the segment growth. Patients undergoing treatments like chemotherapy or dialysis often suffer from muscle wasting and protein deficiencies, boosting demand for protein-enriched medical foods. In addition, the aging population, particularly in developed countries, further contributes to the need for protein modules to combat age-related muscle loss (sarcopenia).

The hypoallergic module segment is anticipated to grow at the fastest CAGR during the forecast period. The growth is driven by the increasing prevalence of food allergies and intolerances, especially among infants and individuals with chronic health conditions. Hypoallergenic medical foods cater to patients with specific dietary needs, such as those unable to tolerate proteins found in common foods like cow's milk or soy. These products are formulated to minimize allergenic responses and are crucial for managing conditions like severe food allergies, eosinophilic esophagitis, and gastrointestinal disorders. The rising awareness of food-related health issues and advancements in hypoallergenic formulations, such as amino acid-based or extensively hydrolyzed proteins, are expected to further support segment expansion over the forecast period.

Sales Channel Insights

The Direct-to-consumer (DTC) sales channel segment held the largest share of 60.9% in 2025 and is expected to grow at the fastest CAGR during the forecast period. DTC sales have emerged as a significant channel within the medical foods market, providing opportunities for manufacturers to engage directly with consumers and tailor their offerings to meet specific health needs. DTC sales in the medical foods sector allow companies to bypass traditional retail channels and establish a direct relationship with end users. This model has gained traction due to its ability to provide personalized customer experiences and strengthen brand loyalty. By leveraging online platforms, companies can offer detailed product information, educational resources, and tailored recommendations based on individual health conditions.

To learn more about this report, Download Free Sample Report

The institutional sales segment is anticipated to grow significantly over the forecast period. The segment's growth is driven by increasing recommendations from doctors to use medical foods. Institutions that purchase medical foods include hospitals, long-term care centers, hospices, clinics, and disability facilities. Since the consumption of medical foods is recommended under medical supervision, the revenue generated through institutional sales is the highest. In addition, training programs for healthcare professionals on the benefits of medical foods further enhance their adoption within institutions. As awareness grows among clinicians about the efficacy of these products in improving patient outcomes, institutional sales are expected to witness significant growth.

Country Insights

China Medical Foods Market Trends

The China medical foods market dominated with a share of 33.0% in 2025, due to an increasing geriatric population and growing FSMP approvals. A UN report indicates that the elderly population in China is projected to double from 10% in 2017 to 20% by 2037. This growing geriatric demographic, along with higher per capita healthcare spending and the growing prevalence of esophageal cancer, is anticipated to be a key market driver.

Japan Medical Foods Market Trends

The medical foods market in Japan is driven by the growing geriatric population. Regulatory support and streamlined approval processes for medical foods in Japan, along with advancements in product formulation and innovation, are contributing to market expansion. For instance, in August 2024, Wada Calcium Pharmaceutical, a company with over 110 years of expertise in calcium-based products, launched a new Food with Function Claims (FFC) designed to enhance bone and immune health in older adults. Their latest offering, the "Bone Density & Immune Care Tablet," is the company’s first FFC formulated with calcium maltobionate and postbiotics. This product incorporates Kirin’s Lactococcus lactis strain Plasma (LC-plasma) postbiotics, along with its signature calcium maltobionate, to support overall health in aging individuals.

India Medical Foods Market Trends

The medical foods market in India is expected to grow at the fastest CAGR of 6.7% over the forecast period, driven by the rising prevalence of malnutrition and diabetes. The increasing burden of diabetes is expected to fuel demand for specialized nutritional products designed to support disease management and address associated nutritional requirements. According to the India Diabetes (INDIAB) study published by the Indian Council of Medical Research (ICMR) in 2023, around 1.2 million people have diabetes, highlighting the substantial disease burden and potential demand for medical foods.

Key Medical Foods Company Insights

Some of the key players operating in the market include Danone, Nestlé, Fresenius Kabi AG and Abbott. Key innovators in the market are utilizing strategies like new product launches to enhance their market presence. For instance, Nestlé, a global player in specialized nutrition, has been actively expanding its range of medical nutrition products in Vietnam. Its offerings include products like Peptamen, a specialized formula for patients with compromised gastrointestinal function, and Resource, aimed at addressing malnutrition in the elderly and individuals recovering from illness.

Key Medical Foods Companies

• Mead Johnson & Company, LLC

• SHS International Ltd

• Synutra International Ltd

• Milupa Gmbh

• Danone

• Nestlé

• Abbott

• Fresenius Kabi AG

• GSK plc

Recent Developments

• In February 2026, Life Health Foods India Pvt. Ltd. launched a high-protein, plant-based beverage range designed to support active and balanced lifestyles. The product portfolio expanded nutritional offerings by providing consumers with convenient protein-rich alternatives aligned with the growing demand for health-focused dietary products.

• In September 2024, Dutch Medical Food B.V. and Pristine Pearl Pharma Pvt. Ltd. collaborated to introduce specialized medical nutrition solutions in India. The initiative aimed to enhance patient care by expanding access to targeted nutritional products and addressing the evolving dietary requirements of patients.

• In August 2024, Avesthagen and Apollo AyurVAID launched medical foods and nutritional supplements in India, combining nutrigenomics-based research with Ayurveda-inspired formulations. The initiative expanded specialized nutritional offerings and targeted personalized dietary management, reflecting growing demand for evidence-based products addressing diverse health and nutritional requirements.

• In September 2023, Danone announced a EUR 50 million (USD 53.78 million) line expansion of its production facility at Opole, Poland, to meet the increasing demand for medical nutrition worldwide. This move aims to enhance its position in the adult medical nutrition market, with the growing rate of chronic diseases and an aging population. The expansion is anticipated to enable Danone to serve patients across the globe, as many people are expected to require medical nutrition at some point in their lives due to diseases such as cancer and stroke, which can result in malnutrition.

• In April 2023, Danone acquired ProMedica, a Poland-based company that specializes in providing care services for patients in their homes. This acquisition is part of Danone's lucrative specialized nutrition market expansion strategy to strengthen its presence in Poland.

• In February 2023, Neslte and EraCal Therapeutics entered into a research collaboration to identify novel nutraceuticals relevant to controlling food intake.

Asia Pacific Medical Food Market Report Segmentation

This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Asia Pacific medical foods market report based on route of administration, product, application, modules, sales channel, and country:

• Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)

  • Oral

  • Enteral

• Product Outlook (Revenue, USD Billion, 2021 - 2033)

  • Pills

  • Powder

  • Liquid

  • Others (semisolid, semiliquid)

• Application Outlook (Revenue, USD Billion, 2021 - 2033)

  • Chronic Kidney Disease

  • Minimal Hepatic Encephalopathy

  • Chemotherapy Induced Diarrhoea

  • Pathogen Related Infections

  • Diabetic Neuropathy

  • ADHD

  • Depression

  • Alzheimer's Disease

  • Nutritional Deficiency

  • Orphan Diseases

    • Tyrosinemia

    • Eosinophilic Esophagitis

    • Food Protein Module-induced enterocolitis syndrome (Food Protein Module-induced enterocolitis syndrome (FPIES))

    • Phenylketonuria (PKU)

    • Maple syrup urine disease (Maple syrup urine disease (MSUD))

    • Homocystinuria

    • Others (Urea Cycle Disorder (UCD), Glycogen Storage Disease (GSD), etc.)

  • Wound Healing

  • Chronic Diarrhea

  • Constipation Relief

  • Protein Booster

  • Dysphagia

  • Pain Management

  • Parkinson's Disease

  • Epilepsy

  • Other Cancer related treatments

  • Severe Protein Allergy

  • Cancer

  • Cachexia

  • Other (debilitating conditions, COPD, etc.)

• Modules Outlook (Revenue, USD Billion, 2021 - 2033)

  • Amino Acid Module

  • Protein Module

  • Vitamin & Mineral Modules

  • Fatty Acid based Modules

  • Carbohydrate Modules

  • Fiber Modules

  • Ketogenic Modules

  • Peptide based Modules

  • Hypoallergic Modules

  • Others (Electrolyte Module, etc.)

• Sales Channel Outlook (Revenue, USD Billion, 2021 - 2033)

  • DTC Sales Channel

    • Online Sales

    • Retail Sales

  • Institutional Sales

    • Hospitals

    • Others (Long-term Care Facilities, etc.)

• Country Outlook (Revenue, USD Billion, 2021 - 2033)

  • Japan

  • China

  • Australia

  • India

  • South Korea

  • Thailand

  • Vietnam

  • Malaysia

  • Indonesia

  • Singapore

Research Methodology

The Asia Pacific medical foods market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each Asia Pacific medical foods segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

This report has been delivered with the following In-depth customizations